Will Battershill and Hollie Wheat from Delta Hat discuss key insights into HTA decision-making from ISPOR Europe. Will explores the hot topic of incorporating patient and carer perspectives into decision-making, whilst Hollie dives into the use of surrogate endpoint evaluation in HTA decision-making.
We delve into ICER’s influence on drug pricing and access in the US. We also explore the importance of maximising engagement with ICER for favourable pricing and access outcomes.
We bring together specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024-25. Jump in, as our experts give their hot-take on each trend, sharing their perspectives on what’s happening in these areas.
What actions can you take in light of ISPOR’s top 10 HEOR trends? What impact may these issues have on your HEOR and Market Access strategy?
Araadhna Sinha tells us about her research evaluating NICE’s new disease severity modifier. Including the impact it could have had on past Health Technology Assessments.
Edyta Ryczek tells us about her research into the inclusion of Carer Health-Related Quality of Life measures in NICE Appraisals
Elizabeth Thurgar tells us about her ISPOR poster reviewing fast-track appraisals at NICE and the evolution of cost comparison
Laura Mathers tells us about her research assessing surrogate endpoints and their impact on HTA recommendations – ISPOR Posters
© 2024 Mtech Access. All rights reserved. Privacy policy. Cookie Settings. Sitemap